Cost-Consequences of Cladribine Tablets for the Treatment of Highly Active Relapsing–Remitting Multiple Sclerosis in Italy
Cladribine tablets are associated with a benefit in terms of prolonging the non-relapsing phase in patients with HA-RRMS, as well as substantial direct cost savings in comparison with all other DMTs. Our analysis suggests that adopting cladribine tablets for HA-RRMS enables clinical benefits over a 4-year time horizon and savings for Italian society.
Authors
- Caterina Rizzi
- Aldesia Provenzano (ORCID: https://orcid.org/0000-0002-4249-8412)
- Barbara Polistena (ORCID: https://orcid.org/0000-0002-0138-0223)
- Elena Colombo (ORCID: https://orcid.org/0000-0002-5265-5055)
- Roberto Bergamaschi
Institutions
- University of Rome Tor Vergata (IT)
- Merck Serono S.p.A. (Italy) (IT)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-06-03
- DOI
- https://doi.org/10.1007/s40120-025-00761-7
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Merck